Compare prices and buy Pinealon from 20 research peptide vendors - also called suppliers or sources. Updated daily.
A synthetic tripeptide, Glu-Asp-Arg (EDR, C15H26N6O8, CAS 175175-23-2), from Vladimir Khavinson's short-peptide program at the Saint Petersburg Institute of Bioregulation and Gerontology. Despite the name, its developers describe it as a neuroprotective peptide isolated from Cortexin, an extract of calf brain cortex. Its published studies are cell-culture and rodent experiments on oxidative stress, hypoxia and Alzheimer's disease models, mostly from the developers' own institute, and its human data come from small Russian studies with no described blinding. It is registered in Russia as a dietary supplement and has no FDA approval.
For research purposes only. Not medical advice.
Pinealon is a synthetic tripeptide, Glu-Asp-Arg (written EDR), from Vladimir Khavinson's bioregulator program at the Saint Petersburg Institute of Bioregulation and Gerontology, which also produced Epitalon and Cartalax. The rest of the family is in Longevity and Bioregulators.
Its identity is settled. The developers' Russian patent, filed in 2006, claims H-Glu-Asp-Arg-OH, their reviews list it as Pinealon (EDR), and the National Library of Medicine's MeSH vocabulary files pinealon as glutamyl-aspartyl-arginine. The formula is C15H26N6O8, and PubChem and the EPA's curated DSSTox chemical database both pair it with CAS 175175-23-2.
The name points to the pineal gland, but the developers' papers point to the brain cortex. Their 2020 review describes Pinealon as a tripeptide isolated from Cortexin, a polypeptide extract of calf brain cortex, and their tables classify it as a neuroprotector. In the group's 2011 study of cultured rat pineal tissue, Epitalon raised markers of pineal cell growth and secretion while Pinealon raised neither. The group's papers call such synthetic short peptides cytogens.
Everything here is preclinical, and most of it comes from Khavinson's institute or groups publishing with its staff.
The only cell or animal test found from outside that circle is an unreviewed 2026 preprint from a Spanish laboratory, which reported a trend toward better working memory in five mice per group over eight weeks.
The group's proposed mechanism is that short peptides enter the cell nucleus and bind DNA and histones to change gene expression. For Pinealon that rests on a labelled peptide entering the nuclei of cultured cells, binding assays with DNA and histones, docking models, and a 2019 physics study from Saint Petersburg State University of it binding DNA in solution. The papers name no receptor for it.
The developers' patent describes 25 patients with long-term effects of traumatic brain injury, randomly split between the peptide and saline, and reports better attention-test and EEG results in the treated groups. It does not describe blinding, and PeptideScouter found the study reported only in the patent and the group's reviews.
Several small Russian-language studies gave it, often alongside Vesugen, to patients with chronic brain conditions, locomotive crews and truck drivers. None of their English abstracts describes a placebo group or blinding. One, from 2015, reported a pro-oxidant effect and a fall in circulating CD34-positive blood stem cells in people given Pinealon or Vesugen, which its authors read as suppressed blood-cell formation.
PeptideScouter found no US regulatory record for Pinealon. As of October 20, 2026, it appears in none of these:
In Russia, the state-registration register of Rospotrebnadzor, the consumer-protection agency, lists Pinealon tablets, capsules and sublingual drops as dietary supplements described as a source of peptides. That registration falls under the customs union's food-safety regulations. Medicines are registered separately.
Not according to its developers. Despite the name, the Khavinson group's 2020 review describes Pinealon as a tripeptide isolated from Cortexin, a polypeptide extract of calf brain cortex, and the group's tables list it as a neuroprotector. In the group's 2011 study of cultured rat pineal tissue, Epitalon raised markers of pineal cell growth and secretion while Pinealon raised neither. Epitalon, designed as an analog of a pineal extract, is the program's pineal peptide.
Only in small studies, and ClinicalTrials.gov lists none of them as of October 2026. The developers' 2006 Russian patent describes 25 patients with long-term effects of traumatic brain injury, randomly split between the peptide and saline, and reports better attention-test and EEG results in the treated groups without describing blinding. Several small Russian-language studies gave it to patients with chronic brain conditions, locomotive crews and truck drivers, and none of their English abstracts describes a placebo group or blinding. One 2015 study reported a pro-oxidant effect and a fall in circulating CD34-positive blood stem cells in people given Pinealon or the related peptide Vesugen.
In the United States it has none. As of October 20, 2026, Pinealon does not appear in Drugs@FDA, in either table of FDA's Category 2 list of bulk drug substances raising significant safety risks, in FDA's lists of substances nominated for compounding under Sections 503A and 503B, or among the substances FDA named for its July 2026 and next Pharmacy Compounding Advisory Committee meetings. FDA's substance registry has no record of it and no FDA warning letter names it. In Russia, the Rospotrebnadzor register lists Pinealon tablets, capsules and sublingual drops as dietary supplements, a food registration and not a medicine approval.
It fits. The number passes the CAS check digit, PubChem resolves both the name Pinealon and the number to the same record for Glu-Asp-Arg with the formula C15H26N6O8, and the EPA's DSSTox chemical database, which marks its record as expert-curated, carries the same pairing. NLM's MeSH vocabulary and the ChEBI database list the tripeptide without a CAS number, and FDA's substance registry has no record of it. The number describes the free peptide, molecular weight about 418, while the developers' patent describes an acetate salt.
Pinealon is sold by 20 research peptide vendors indexed on PeptideScouter, with 29 tracked listings compared per vendor in the table above. Pricing is normalized and refreshed daily.
18 of the 20 indexed vendors currently have Pinealon in stock. The comparison table marks out-of-stock listings, and stock state is refreshed daily.
Studz Peptides currently lists Pinealon at $2.11/mg, the lowest listed price across 20 tracked research peptide vendors. With current vendor discount codes applied, the lowest effective price is $1.90/mg.
Discount codes are issued per vendor rather than per peptide, so any code applies across that vendor's whole catalog. All 20 vendors listing Pinealon publish a PeptideScouter code, worth 5% to 50% off. Applied, the lowest effective price falls from $2.11/mg listed to $1.90/mg at Studz Peptides. Each vendor's code is shown beside its price in the table above.
Pinealon ranges from $2.11/mg to $7.70/mg across 29 listings from 20 research peptide vendors, normalized to USD per milligram and refreshed daily.
20 research peptide vendors currently list Pinealon on PeptideScouter, with 18 in stock right now. We track 29 listings across size and kit variants.
Pinealon's CAS Registry Number is 175175-23-2.
